iBio Share Price

iBio Share Price

NASDAQ: IBIO | Healthcare
$0.00
+0.00 (0.00%)
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

iBio Stock Performance

Open
N/A
Prev. Close
N/A
Circuit Range
N/A
Day Range
N/A
Year Range
N/A
Volume
N/A
Average Traded
N/A

iBio Share Price Chart

Line chart of the iBio price trend over the selected period. The price rose overall, ranging from 0.77 to 0.82, ending at 0.82.
$0.00$0.00
L
Show Current Price
H

iBio Stock Fundamentals & Key Indicators

Market Cap
N/A
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.37
Revenue (TTM)
$100.00M
Return On Equity (TTM)
-32.95%
Profit Margin
-33040.00%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
N/A

iBio Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$1.08
Net Profit$0.00-$7.76-$10.58-$7.55
Net Profit MarginN/AN/AN/A-699.07%
Income ChangeN/AN/A-36.34%28.64%

iBio Annual Profit & Loss

All figures in USD

Particulars2023202420252026
Revenue$0.00$0.23$0.40$0.10
Net Profit-$65.01-$24.91-$18.38-$33.04
Net Profit MarginN/A-10830.43%-4595.00%-33040.00%
Income ChangeN/A61.68%26.21%-79.76%

iBio Balance Sheet

All figures in USD Million

Particulars2026202520242023
Non Current Assets6.8913.4613.0614.95
Current Assets92.229.7215.6726.26
Total Assets99.1123.1928.7341.21
Non Current Liabilities1.652.23.573.72
Current Liabilities11.756.113.8422.11
Total Liabilities13.48.317.4125.83
Shareholders' Equity85.7114.8821.3215.38

iBio Cash Flow

Annually

All figures in USD Million

Particulars2026202520242023
Operating-23.22-15.3-18.55-30.42
Investing-32.00.740.916.99
Financing103.058.9324.492.3

Corporate Actions

Split
Ex-date: 29 Nov 2023

Split
Ex-date: 10 Oct 2022

Split
Ex-date: 11 Jun 2018

About iBio

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

iBio Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %

iBio Share Price FAQs